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Introduction {#sec001}
============

Endothelins (ETs) are potent vasoactive peptides that play important roles in homeostatic control of vessel tone in healthy individuals as well as being implicated in a number of disease states \[[@pone.0151810.ref001]\]. Observations of ET system dysfunction observed in both experimental animal models and clinical studies of cardiovascular \[[@pone.0151810.ref002]--[@pone.0151810.ref004]\] and pulmonary \[[@pone.0151810.ref005]--[@pone.0151810.ref007]\] disease have led to the identification of the endothelin system as a therapeutic target. Patients with pulmonary artery hypertension display increased ET-1 plasma levels and treatment with ET receptor antagonists in experimental models and clinical trials have shown a reduction in pulmonary vascular pressure, right ventricular hypertrophy and pulmonary artery wall thickening \[[@pone.0151810.ref008], [@pone.0151810.ref009]\]. Both selective and non-selective ET receptor antagonists (ambrisentan, and bosentan, respectively) are currently employed for treatment of pulmonary artery hypertension \[[@pone.0151810.ref009], [@pone.0151810.ref010]\]. Endothelin-1 is also a pro-fibrotic factor, and bosentan has been approved for treatment of the fibrosis disease scleroderma \[[@pone.0151810.ref009]\]. Although promising in vivo data suggest that treatment with ET receptor antagonists can produce beneficial outcomes in models of cardiovascular disease \[[@pone.0151810.ref011]--[@pone.0151810.ref013]\], results in clinical trials have proven less definitive.

Oxidative stress is implicated in many disease states, and has been shown to play a role in regulating ET levels \[[@pone.0151810.ref014]--[@pone.0151810.ref017]\], which in turn can modulate production of reactive oxygen species \[[@pone.0151810.ref018]--[@pone.0151810.ref020]\]. For example, oxidative stress-induced increases in preproET-1 mRNA were abolished by superoxide dismutase \[[@pone.0151810.ref014]\]. Conversely, production of reactive oxygen species following treatment of fetal pulmonary artery smooth muscle cells with ET-1 was attenuated by antioxidant treatment \[[@pone.0151810.ref019]\]. Clinical studies have shown a positive correlation of antioxidant levels and ET-1 expression \[[@pone.0151810.ref021], [@pone.0151810.ref022]\]. Taken together, these studies indicate that oxidative stress activates the endothelinergic system, an effect that can be mitigated by antioxidants.

The importance of oxidative stress in disease processes has led to the development of antioxidant therapeutics. Metalloporphyrin complexes mimic the biologic activity of superoxide dismutase, including scavenging of superoxide, H~2~O~2~, peroxynitrite, and lipid peroxyl radicals \[[@pone.0151810.ref023], [@pone.0151810.ref024]\], and can pharmacologically augment natural antioxidant defenses \[[@pone.0151810.ref025]\]. The superoxide dismutase mimetic manganese (III) mesotetrakis (di-N-ethylimidazole) porphyrin AEOL 10150 is a low molecular weight, synthetic, redox-active, catalytic antioxidant that was shown in rodent models to attenuate expression of inflammatory genes in stroke \[[@pone.0151810.ref026]\] and to reduce tobacco smoke-induced inflammation and lung injury when delivered by intratracheal instillation before smoke exposure \[[@pone.0151810.ref027]\]. Recent studies demonstrate AEOL 10150 as an effective rescue treatment following exposure to chlorine gas and 2-chloroethyl ethyl sulfide through reduction in inflammation, lung injury, and oxidative stress \[[@pone.0151810.ref028], [@pone.0151810.ref029]\]. There is some evidence that metalloporphyrin catalytic antioxidants can exert hypotensive effects in rats \[[@pone.0151810.ref030]\], but effects on the ET system have not been examined.

The aim of this study was to characterize the impact of the superoxide dismutase mimetic AEOL 10150 on circulating ET peptide levels and expression of endothelin system genes. For this purpose, we chose to use an inbred normotensive healthy rat model (Fischer 344) since we were interested in the impact of AEOL 10150 on a healthy cardiovascular system. We treated these rats with AEOL 10150 and followed the oxidative stress levels and circulating endothelin profiles.

Materials and Methods {#sec002}
=====================

Animals {#sec003}
-------

Pathogen-free Fischer-344 male rats (180--250g) were obtained from Charles River (St. Constant, Québec, Canada). The animals were housed in individual Plexiglas cages on wood-chip bedding under HEPA-filtered air and held to a 12h dark/light cycle. Food and water were provided ad libitum. All experimental protocols were reviewed and approved by the Animal Care Committee of Health Canada (Ottawa, Ontario, Canada).

Subcutaneous Injections {#sec004}
-----------------------

AEOL 10150 (manganese (III) meso-tetrakis (di-N-ethylimidazole) porphyrin), a superoxide dismutase mimetic, is a stable, nontoxic, water soluble compound with a superoxide dismutase activity of \~5,000 units/g and catalase activity of approximately \~1% of purified bovine catalase (weight/weight basis). Animals were randomized initially prior to any treatment and were weighed. In this study AEOL 10150, a gift from Incara Pharmaceuticals (Research Triangle Park, NC, USA), was subcutaneously injected into animals at concentrations 0, 2 or 5 mg/kg body weight (BW) in 1 mL/kg BW of saline at 8am (n = 6 animals per group). Sample size was determined based on our previous work. The mode of drug administration was based on previous literature \[[@pone.0151810.ref031]\]. All treatments and assessments were randomized to avoid any bias.

Biological Samples {#sec005}
------------------

Rats were anaesthetized at 2h or 24h following dosing with AEOL 10150 by administration of sodium pentobarbital (60 mg/kg, ip). Blood was collected from the abdominal aorta and combined with protease inhibitors (10 mg/mL ethylene diamine tetra acetic acid (EDTA) and 1.7 mg/mL phenyl methyl sulfonyl fluoride (PMSF) \[[@pone.0151810.ref032]\]. The animals were then exsanguinated, and the trachea was exposed and cannulated. The diaphragm was punctured to collapse the lungs, and the lungs were filled by intratracheal instillation of warm (37°C) calcium- and magnesium-free Dulbecco\'s phosphate buffered saline (Sigma Chemical Co., St. Louis, MO) at a ratio of 35 mL/kg BW. The saline was aspirated and re-injected twice more, and the bronchoalveolar lavage fluid was recovered. This lavage fluid was further used for total protein analysis as previously described \[[@pone.0151810.ref033]\]. The lungs and heart were recovered, flash frozen in liquid nitrogen, and stored at -80°C.

Plasma Samples {#sec006}
--------------

Briefly, blood samples were centrifuged at 1448 x g for 10 min to obtain plasma. Plasma samples were recovered and vortexed with 50 μL of aqueous 0.1M DETPA solution and 50 μL of 0.3M BHT solution in isopropanol to prevent any post-mortem changes due to autoxidation. Two sets of plasma aliquots (250 μL) were used for 8-isoprostane and for protein oxidation, nitration marker analyses, while another set of aliquots was used for analysis of circulating endothelin levels.

Plasma Isoprostane {#sec007}
------------------

Aliquots of plasma (250 μL) samples stabilized with DETPA and BHT were used for the 8-isoprostane (15(s)-8-iso-PGF2α)analysis. Plasma samples were purified initially using C18 cartridges and were analysed using a competitive enzyme immunoassay kit (Cayman Chemicals, Ann Arbor, Michigan, USA) following a procedure reported earlier \[[@pone.0151810.ref034]\].

Plasma 3-Nitrotyrosine {#sec008}
----------------------

Nitrative stress levels in rat plasma were measured by analysis of protein nitration product 3-nitrotyrosine using the HPLC-Coularray method described previously \[[@pone.0151810.ref035]\]. Here, 250 μL aliquots of plasma samples stabilized with DETPA and BHT were deproteinized by use of acidified acetone, evaporated to concentrate, clarified using molecular weight cut-off filters (30 kDa), dried under N~2~ flow and were reconstituted with 100 μL of acidified water prior to the analysis by the HPLC-Coularray method. Initial separation of analytes were carried out on a LC-18 reversed phase column (25 cm length, 4.6 mm id, 5μm particle size; Supelco, Oakville, ON) by isocratic elution using a citrate-acetate buffer (pH = 4.7) mobile phase containing OSA as the ion-pair reagent. Separated analytes were measured by coulometric array detection using a set of eight electrodes at different applied potentials.

Plasma Endothelins {#sec009}
------------------

This procedure was conducted using a previously reported method \[[@pone.0151810.ref032]\]. Briefly, plasma aliquots (250 μL) were treated with 3,4-dichloroisocoumarin solution in isopropanol to prevent conversion of big ET-1 (BET-1) to ET-1 during sample processing. Samples were deproteinized by acidified acetone, evaporated to concentrate, and then cleaned up using molecular weight cut-off filters (30 kDa). Clarified samples were dried under a N~2~ flow and were reconstituted in phosphate buffered saline and were analyzed by a reversed phase HPLC-Fluorescence system. Initial separation of endothelin isoforms was carried out on a LC-318 column (25 cm length, 4.6 mm id, 5μm particle size; Supelco, Oakville, ON) by gradient elution using water-acetonitrile mobile phase \[A-30% acetonitrile (aq); B-90% acetonitrile (aq)\] with 0.19% of TFA used as the ion-pair reagent. Analytes were measured by fluorescence detection at excitation and emission wavelengths of 240 nm and 380 nm, respectively.

Gene Expression {#sec010}
---------------

Real-time reverse transcription polymerase chain reaction (RT-PCR) was conducted using validated primer sets as previously described \[[@pone.0151810.ref036]\]. Double-desalted primers for β-actin, preproET-1, ECE-1, ET~A~ receptor, ET~B~ receptor, eNOS and iNOS were purchased from Invitrogen, Canada. Briefly, frozen lung and heart samples were homogenized in TRIzol reagent (Invitrogen Canada Inc., Burlington, Ontario, Canada), and total RNA was isolated according to the manufacturer's instructions. RNA was quantified using the RiboGreen RNA Quantitation Reagent and Kit (Molecular Probes, Eugene, OR, USA), and total RNA was reverse transcribed using MuLV reverse transcriptase and random hexamers (Applied Biosystems, Mississauga, Ontario, Canada) according to the manufacturer's instructions. Twenty nanograms cDNA was incubated with 25 μL iQ SYBR Green Supermix (Bio-Rad Laboratories (Canada) Ltd., Mississauga, Ontario, Canada) and 200 nM of each primer, and the reagent mixture was brought up to 50 μL with DNase/RNase-free water. All reactions were performed in duplicate on 96-well plates in a spectrofluorometric thermal cycler (iCycler iQ, Bio-Rad, Bio-Rad Laboratories (Canada) Ltd., Mississauga, Ontario, Canada). Uniform reaction conditions were confirmed as previously described \[[@pone.0151810.ref037]\]. PCR runs were initiated by incubation at 95°C for 3 min to activate the iTAQ polymerase followed by 40 cycles of 95°C for 15 s, the appropriate annealing temperature for 15 s (60°C for ET~B~ receptor and 62°C for all other genes), and 30 s at 72°C. Fluorescence was monitored at every cycle during the elongation step. A melt curve was conducted following each run to verify product purity. Expression was calculated relative to β-actin using the delta-Ct method \[[@pone.0151810.ref038]\], and expressed as fold change relative to control samples.

Statistical Analyses {#sec011}
--------------------

Statistical significance was assessed by 2-way ANOVA with AEOL (0, 2, 5 mg/kg BW) and TIME (2, 24h) as factors (n = 6 animals per group), followed by Holm-Sidak multiple comparison procedure to elucidate the pattern of significant effects (α = 0.05). Data are expressed as mean ± SEM.

Results {#sec012}
=======

Oxidative and Nitrative Stress {#sec013}
------------------------------

To confirm the antioxidant actions of AEOL 10150, we measured plasma levels of two markers of oxidative stress, 8-isoprostane and 3-nitrotyrosine. Levels of 8-isoprostane were significantly decreased (p\<0.05) in animals injected with 2 mg/kg AEOL 10150 and tended to decrease at 5 mg/kg (not statistically significant) at both 2 and 24h post exposure ([Fig 1A](#pone.0151810.g001){ref-type="fig"}). 3-Nitrotyrosine exhibited a dose-dependent decrease (p\<0.05) in rats injected with 2 and 5 mg/kg body weight AEOL 10150 ([Fig 1B](#pone.0151810.g001){ref-type="fig"}).

![Plasma levels of isoprostane and 3-nitrotyrosine in animals treated with AEOL.\
Mean ± SE, n = 6 animals per group. **A**. Plasma isoprostane: Two-way ANOVA. AEOL main effect, p = 0.036. Holm-Sidak: **a**, 0 vs 2 mg/kg, p = 0.011. **B**. Plasma 3-nitrotyrosine: Two-way ANOVA. AEOL main effect, p = 0.003. Holm-Sidak: **b**, 0 vs 5 mg/kg, p \< 0.001, and 2 vs 5 mg/kg, p \< 0.040.](pone.0151810.g001){#pone.0151810.g001}

Plasma Endothelin {#sec014}
-----------------

Plasma endothelins (BigET-1, ET-1, ET-2, and ET-3) levels were analysed to investigate the impact of this antioxidant treatment on these vasoactive peptides. Plasma ET-1 and ET-3 levels were found to be decreased significantly (p\<0.05) at the -5 mg/kg BW dose and at both 2h and 24h post-exposure ([Fig 2](#pone.0151810.g002){ref-type="fig"}). No statistically-significant changes in bigET-1 and ET-2 were detected, although treatment with AEOL 10150 tended to decrease plasma ET-2.

![Plasma levels of bigET-1, ET-1, ET-2 and ET-3 peptides in animals treated with AEOL.\
Mean ± SE, n = 6 animals per group. **A.** BigET-1: NS. **B.** ET-1: Two-way ANOVA. TIME main effect, p = 0.042. Holm-Sidak: **a**, 2 h vs 24 h, p \< 0.05. AEOL main effect, p = 0.001. Holm-Sidak: **b**, 0, 2 vs 5 mg/kg, p \< 0.001. **C.** ET-2: NS. **D.** ET-3: Two-way ANOVA. AEOL main effect, p = 0.014. Holm-Sidak: **c**, 2 vs 5 mg/kg, p = 0.004.](pone.0151810.g002){#pone.0151810.g002}

Endothelin System Genes Expression in Lungs and Heart {#sec015}
-----------------------------------------------------

Lung and heart preproET-1 mRNA levels exhibited an increasing trend 2h after exposure at the highest dose of AEOL 10150, but the changes did not reach statistical significance ([Fig 3A and 3B](#pone.0151810.g003){ref-type="fig"}). Endothelin converting enzyme (ECE)-1 mRNA expression was unchanged in the lung following AEOL 10150 injection ([Fig 3C](#pone.0151810.g003){ref-type="fig"}), but was increased (p\<0.05) in the heart tissue 2h and 24h after treatment at 5 mg/kg ([Fig 3D](#pone.0151810.g003){ref-type="fig"}). Expression of the ET~A~ receptor mRNA was found to be significantly decreased (p\<0.05) in the lungs of animals injected with 5 mg/kg dose of the drug at both 2h and 24h post exposure ([Fig 4A](#pone.0151810.g004){ref-type="fig"}), but not in the heart ([Fig 4B](#pone.0151810.g004){ref-type="fig"}). Meanwhile, ET~B~ receptor mRNA expression was significantly reduced (p\<0.05) in the lungs of animals at 24h post-treatment ([Fig 4A](#pone.0151810.g004){ref-type="fig"}). There were no significant changes in heart ET~B~ receptor mRNA expression 2h and 24h after treatment with the drug ([Fig 4B](#pone.0151810.g004){ref-type="fig"}).

![Lung and heart preproET-1 and ECE-1 mRNA.\
Mean ± SE, n = 6 animals per group. **A.** Lung preproET-1 mRNA: NS. **B.** Heart preproET-1 mRNA: NS. **C.** Lung ECE-1 mRNA: NS. **D.** Heart ECE-1 mRNA: Two-way ANOVA. TIME x AEOL interaction, p = 0.006. Holm-Sidak: **a**, AEOL within 2 h: 0, 2 vs 5 mg/kg, p\<0.05. **b**, AEOL within 24 h: 2 vs 5 mg/kg, p = 0.029.](pone.0151810.g003){#pone.0151810.g003}

![Lung and heart ET~A~ receptor and ET~B~ receptor mRNA.\
Mean ± SE, n = 6 animals per group. **A.** Lung ET~A~R. Two-way ANOVA. AEOL main effect, p = 0.045. Holm-Sidak: **a** 0 vs 5 mg/kg, p = 0.014. **B.** Heart ET~A~ mRNA: NS. **C.** Lung ET~B~R: Two-way ANOVA. TIME main effect, p = 0.028. Holm-Sidak: **b**, 2 vs 24 h, p \< 0.05. **D.** Heart ET~B~ mRNA: NS.](pone.0151810.g004){#pone.0151810.g004}

eNOS and iNOS Gene Expressions in Lungs and Hearts {#sec016}
--------------------------------------------------

No statistically-significant changes in eNOS mRNA levels were observed in the lungs or heart ([Fig 5A and 5B](#pone.0151810.g005){ref-type="fig"}). However, lung iNOS mRNA expression significantly increased (p\<0.05) at 5 mg/kg within 2h after injection of the drug but decreased afterward, down by 40% (p\<0.05) 24 h post-treatment ([Fig 5C](#pone.0151810.g005){ref-type="fig"}). Changes of iNOS mRNA expression in the heart tissue were not statistically-significant ([Fig 5D](#pone.0151810.g005){ref-type="fig"}).

![Lung and heart eNOS and iNOS mRNA.\
Mean ± SE, n = 6 animals per group. **A.** Lung eNOS: NS. **B.** Heart eNOS: NS. **C.** Lung iNOS: Two-way ANOVA. TIME x AEOL interaction, p \< 0.001. Holm-Sidak: **a**, AEOL within 2 h: 0, 2 vs 5mg/kg, p \< 0.001. **b**, AEOL within 24 h: 0 vs 5 mg/kg, p = 0.047. **D.** Heart iNOS: NS.](pone.0151810.g005){#pone.0151810.g005}

Discussion {#sec017}
==========

In the present study, the effect of the manganese superoxide dismutase mimetic AEOL 10150 on basal levels of oxidative stress in vivo and the endothelin system were examined in a healthy rat (Fischer 344) model. AEOL 10150 treatment led to decreased levels in plasma of 8-isoprostane levels, a product of lipid peroxidation, and 3-nitrotyrosine, a marker of oxido-nitrative stress. This confirms the role of this drug as an antioxidant and as a scavenger of superoxide anion that is known to participate in the formation of 8-isoprostane and 3-nitrotyrosine by generation of peroxynitrite species. Our observations are also consistent with the observation of a reduction of oxidative and nitrative stress by the superoxide dismutase mimetic tempol in models of diabetes \[[@pone.0151810.ref039], [@pone.0151810.ref040]\] or spinal cord injury \[[@pone.0151810.ref041]\].

The data revealed that treatment with AEOL 10150 decreased the circulating levels of the mature peptides ET-1 ([Fig 3B](#pone.0151810.g003){ref-type="fig"}) and ET-3 ([Fig 3D](#pone.0151810.g003){ref-type="fig"}) in a statistically-significant manner at the highest dose of 5mg/kg; ET-2 also displayed a trend to decrease but changes were not statistically-significant ([Fig 3C](#pone.0151810.g003){ref-type="fig"}). Plasma levels of the precursor peptide bigET-1 levels were not affected by treatment ([Fig 2A](#pone.0151810.g002){ref-type="fig"}), suggesting that decrease of systemic levels of circulating ET-1 was not due to decreased de novo synthesis. The lung vascular bed is a main source of circulating bigET-1 and ET-1, as well as the main site of receptor-mediated clearance of ET-1. Expressions of preproET-1 mRNA ([Fig 3A](#pone.0151810.g003){ref-type="fig"}) and ECE-1 mRNA ([Fig 3C](#pone.0151810.g003){ref-type="fig"}) in the lungs were not altered by the AEOL 10150 treatments, consistent with minimal impact of the drug on de novo synthesis of bigET-1 and processing of bigET-1 to ET-1 by ECE-1, at least in the lung parenchyma and vascular bed.

The ET~A~ receptor is known to enable vasoconstriction mechanisms in response to binding of mature endothelin peptides, with ET-1 being the most potent \[[@pone.0151810.ref042]\]. Binding to the ET~B~ receptor in the caveola of the lung capillary bed is the principal clearance mechanism of the mature ET-1 peptides; liganding of the ET~B~ receptor in most tissues also triggers NO synthesis and vasodilation responses \[[@pone.0151810.ref043]\]. Previous reports have shown that the loss of ET~B~ receptor led to increased circulating levels of ET-1 in vivo \[[@pone.0151810.ref044], [@pone.0151810.ref045]\]. Here, we show that expression of both ET~A~ and ET~B~ receptors mRNA expression were reduced 24 h after treatment of the animals with AEOL 10150 ([Fig 4A and 4B](#pone.0151810.g004){ref-type="fig"}). It may be that reduced oxidative stress is protective of the receptors during recycling, with decreased turnover and reduced requirement for de novo synthesis; however, the molecular and physiological significance of our observations remain to be established. Certainly, ET~B~/ET~A~ receptor antagonists are associated with a reduction in blood pressure \[[@pone.0151810.ref009], [@pone.0151810.ref046]\], illustrating the physiological relevance of reduced expression of endothelin receptors.

The lung, with its large vascular bed, is an important producer of vasoactive agents including vasoconstrictive endothelins and the vasodilatory molecule nitric oxide. In addition to the effects on endothelin receptor transcript levels, AEOL 10150 treatment resulted in an early increase in lung iNOS mRNA, within 2h after treatment, but followed by a 40% decrease over the following 24h. Interestingly, it has been reported that iNOS activity is essential for activation of antioxidant protection genes in rat aorta endothelial cells \[[@pone.0151810.ref047]\]. The human lung epithelial cells express iNOS and are responsible for most of the bronchodilating NO in exhalate \[[@pone.0151810.ref048]\]. Binding of ET-1 to ET~B~ receptors can lead to downstream signalling of vasodilation pathway through NO production \[[@pone.0151810.ref045]\], and it is possible that this is a favoured early pathway based on the observation of AEOL treatment-related increase of lung iNOS mRNA levels. A protective effect of iNOS on thrombosis in female mice has also been reported \[[@pone.0151810.ref049]\]. Nevertheless, despite early activation, iNOS expression was eventually decreased; it is also possible that AEOL 10150 treatment interfered with the corresponding downstream iNOS enzyme production and/or activity \[[@pone.0151810.ref050]\]. Both ET~B~ receptor and iNOS expression were observed to decline at 24h post AEOL exposure, which may be attributable to homeostatic gene expression mechanisms in response to higher levels of NO and reduced ET-1, as sustained NO production is metabolically toxic \[[@pone.0151810.ref051]\]. Overall, the 40% decrease of iNOS mRNA expression in the lungs, with the 25--30% decreases of isoprostane and 3-nitrotyrosine in plasma after AEOL treatment reported here are consistent with the observation of a reduction of oxidative and nitrative stress by the superoxide dismutase mimetic tempol in such models of diabetes \[[@pone.0151810.ref039], [@pone.0151810.ref040]\] or spinal cord injury \[[@pone.0151810.ref041]\].

Exposure to air pollutants that amplify oxidative stress increases transcript levels of ET genes in several organs and produces higher circulating ET levels \[[@pone.0151810.ref036], [@pone.0151810.ref052], [@pone.0151810.ref053]\]. Inhibition of the reactive oxygen species-generating enzyme xanthine oxidase with oxypurinol has been shown to reduce ET-1 expression and secretion in mammary arteries as well as in patients immediately following angioplasty \[[@pone.0151810.ref015]\]. Endothelin-1 plasma levels are also known to be elevated in hypertensive and diabetic patients, and correlate with lower antioxidant status and vitamin C concentrations \[[@pone.0151810.ref022]\]. In our present study, the decline in plasma markers of oxidative stress correlated with a marked decrease in plasma levels of ET-1 after treatment with AEOL 10150, consistent with the above stated association. As indicated earlier, there were no evidence here of changes in expression of preproET-1 or ECE-1 mRNA expression in the lungs, while the pulmonary expression the clearance receptor ET~B~ was actually reduced by 30% after treatment of the animals with AEOL 10150. Hence, it does not appear that reduction of circulating levels of ET-1 was due to downregulation of expression, decreased rate of maturation, or enhanced receptor-mediated clearance within the lungs. The decreases of circulating levels of ET-1 (p\<0.05), ET-2 (NS) and ET-3 (p\<0.05) could be due to reduced systemic gene expression of the prepropeptides or enhanced clearance by degradation. It is noteworthy that expressions of preproET-1 (NS) and ECE-1 (p\<0.05) were increased in the heart after the higher dose of AEOL 10150. This could possibly represent a compensatory response of the heart to decreased circulating ET-1 that is aimed at maintaining the positive inotropic role of ET-1, which is in part regulated by superoxide flux \[[@pone.0151810.ref054], [@pone.0151810.ref055], [@pone.0151810.ref056]\].

Together, our data indicate that the catalytic antioxidant AEOL 10150 exerts effects on the endothelin/nitric oxide system in this healthy animal model. This is consistent with the reported hypotensive property of the drug \[[@pone.0151810.ref030]\] and a role for reactive oxygen species in the regulation of the endothelinergic system, in vasoconstriction and endothelial dysfunction.

Conclusion {#sec018}
==========

The present study demonstrates that the basal endogenous flux of reactive nitrogen species and reactive oxygen species regulate the homeostatic balance of the endothelin/nitric oxide system. Scavenging of free radicals by AEOL 10150 decreases baseline ET-1 levels likely through accelerated clearance, and may decrease sensitivity to ET-1 through down-regulation of ET~A~ receptor.
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